Access the Preliminary Scientific Program of the SOLACI-CACI 2024 Congress

Check out all the preliminary scientific activities of the SOLACI-CACI 2024 Congress, the largest interventional cardiology meeting in Latin America!

For more information, enter www.solacicongress.org

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

CHIP LATAM | Chapter 2 – Mexico: Complications Workshop

The Latin American Society of Interventional Cardiology invites the entire medical community to participate in a virtual workshop on complications organized by SOLACI’s Complex...

Fellow’s Corner 2026 – Submit Your Clinical Case

Share your experience. Learn from experts. Grow as an interventional cardiologist. The Latin American Society of Interventional Cardiology (SOLACI) is relaunching this year the Fellow’s...

Watch Again: Cardiovascular Risk Factors in Women | SOLACI Technicians Webinar

The webinar “Cardiovascular Risk Factors in Women,” held on January 27, 2026, via the Zoom platform, is now available for viewing on SOLACI’s YouTube...

Technical Training in Hemodynamics and Interventional Cardioangiology | SOLACI–CACI

The SOLACI–CACI Technical Training in Hemodynamics and Interventional Cardioangiology is an academic program designed for the initial training and professional development of non-physician healthcare...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...